Drug Profile
Insulin biosimilars - Bioton
Alternative Names: Insulin analogues; Recombinant insulinsLatest Information Update: 21 Jan 2022
Price :
$50
*
At a glance
- Originator BIOTON
- Class Antihyperglycaemics; Hepatoprotectants; Insulins; Pancreatic hormones
- Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase Unknown Diabetes mellitus
Most Recent Events
- 08 May 2020 Allergan has been acquired and merged into AbbVie
- 20 Jun 2018 Biomm plans a phase I trial for Type-1 diabetes mellitus in comparison with Humulin® in Brazil (RBR7mvgfc)
- 22 May 2018 BIOMM S.A and Instituto de Ciências Farmacêuticas de Estudos e Pesquisas Ltda plans a phase I trial for type 1 Diabetes mellitus in Brazil (RBR8b9npb)